US/UK/Canada

Share

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    • Pick a time period -
    Tags ( Active)

    Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update

    Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that Hansa Medical will publish the 2018 Year-End Report on 8 February 2010, at 08:00AM CET, and that all interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren

    Increase of number of votes in Hansa Medical AB (publ)

    Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s number of votes has changed as a result of the conversion of 13,142 C shares into ordinary shares during January under Hansa Medical’s long-term incentive program.As of January 31, 2019, the total number of registered and outstanding shares of Hansa Medical totals 40,681,654 of which 39,973,032 are

    Hansa Medical Announces Appointment of Anne Säfström Lanner as Vice President, Global Human Resources

    Lund, Sweden, January 18, 2019 -- Hansa Medical AB (NASDAQ Stockholm: HNSA), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced the appointment of Anne Säfström Lanner as Vice President, Global Human Resources.Mrs. Lanner has over 15 years of broad human resources experience in international growth companies, including developing and implementing strategies for talent acquisition and management, organizational culture and employer branding, compensation and benefits, and employee training and development. Prior to

    Hansa Medical AB Provides Regulatory Update for Imlifidase in Kidney Transplantation

    Lund, Sweden, January 15, 2019 - Hansa Medical AB (Nasdaq Stockholm:HNSA) (“Hansa Medical” or the “Company”), a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today provided an update following the Company’s regulatory interactions with the European Medical Agency (EMA) and the U.S. Food and Drug Administration (FDA) for imlifidase in kidney transplantation.“We have had very productive meetings with the EMA and FDA, during which both agencies provided positive feedback on the data generated on imlifidase to date and acknowledged the

    Hansa Medical Interim report April – June 2018

    April – June 2018 in brief ›› Long-term follow-up data from the 17 patients treated with imlifidase in the investigator-initiated Phase II study in highly sensitized patients was presented at the 2018 American Transplant Congress in early June by Professor Stanley C. Jordan, M.D., Director of Nephrology, Cedars-Sinai Medical Center. ›› Patients show good renal function and minimal evidence of antibody-mediated rejection (AMR) at a mean 19 months post kidney transplantation, with graft and patient survival at 94%. ›› Two-year follow-up data demonstrate good patient and graft

    Hansa Medical lead candidate imlifidase (IdeS) granted orphan drug designation by the FDA for anti-GBM antibody disease

    Hansa Medical today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to imlifidase (IdeS) for the treatment of anti-GBM antibody disease (anti-GBM), also known as Goodpastures disease. More information about the orphan drug designation has been posted on www.fda.govAnti-GBM is a severe kidney disease where the immune system mistakenly develops IgG-antibodies, resulting in an acute immune attack on the kidneys and in some patients also on the lungs. In severe anti-GBM, the disease may progress to renal failure or death. There is no approved

    Increase of number of shares in Hansa Medical AB (publ)

    As previously announced, the general meeting of Hansa Medical AB (publ) resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 205,000 ordinary shares have been issued. The company’s registered share capital and number of outstanding shares and votes have thus increased during the month of June 2018.As of today, the total number of registered and outstanding shares of Hansa Medical amounts to 38,413,386 whereof 38,083,125 are ordinary shares and 330,261 are Class C shares. As of today, the number of votes in Hansa Medical amounts to 38,116,

    Hansa Medical’s warrant program TO2015 has opened for exercise and subscription of shares

    The exercise period in the employee warrant program (TO2015) established in June 2015 opened today June 15, 2018 and is ongoing until June 15, 2019.The TO2015 warrant-based incentive program for Hansa Medical employees was implemented following a resolution at the 2015 Annual General Meeting in order to reward and incentivize Hansa Medical employees. The warrants were sold to the company’s employees for an estimated market value of the warrants using the Black & Scholes model. As of today, 205,000 out of 355,000 warrants have been exercised for subscription of shares at the subscription

    Hansa Medical to Host Conference Call to Provide First Quarter 2018 Business Update

    On 25 April 2018, at 08:00AM CET, Hansa Medical will publish its Business Update for the first quarter of 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren Tulstrup, and the presentation will be held in English.Slides used in the presentation will be live on the company’s website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please

    Hansa Medical publishes the Annual Report for 2017

    Hansa Medical's Annual Report for 2017 is now available on the company’s website, www.hansamedical.com. Visit our Annual report 2017 site at http://hansamedical.com/annual-report/2017/ The Annual Report is posted to shareholders and other stakeholders who specifically request it. For further information please contact the company by telephone +46 46-16 56 70 or e-mail info@hansamedical.com.  The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated

    Hansa Medical to Host Conference Call to Provide Year-End Report 2017 Business Update

    On 14 February 2018, at 08:00AM CET, Hansa Medical will publish its report for the year ended 31 December 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s Acting CEO and President, Ulf Wiinberg, and the presentation will be held in English.Slides used in the presentation will be live on the companys website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference,

    Increase of number of votes in Hansa Medical AB (publ)

    The number of votes in Hansa Medical AB (publ) has changed as a result of conversion of in total 70,739 C shares into ordinary shares carried out in January under Hansa Medical’s long-term incentive programme.As of January 31, 2018, the total number of registered and outstanding shares of Hansa Medical amounts to 38,208,386 of which 37,878,125 ordinary shares, together carrying 37,878,125 votes, and 330,261 C shares, together carrying 33,026.1 votes. The total number of votes in Hansa Medical is 37,911,151.1.   This information is information that Hansa Medical AB (publ) is obliged to

    Completed enrollment in Hansa Medical’s international multi-center Phase II study Highdes

    Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, announced today the completion of enrollment for the international multi-center study Highdes.The study aimed to recruit 15-20 patients. A total of 18 patients have been treated with the company’s lead candidate IdeS and subsequently transplanted at five clinics in the US and Europe. All treated and transplanted patients will be followed up for six months. The primary objective of the study - to turn a positive cross-match test into a negative and thereby enable kidney

    Finalized enrollment in US Phase II study with IdeS in highly sensitized patients

    Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, announced today that enrollment has been finalized in the US investigator-initiated Phase II study with lead candidate IdeS in highly sensitized patients.A total of 17 patients have been enrolled in the study (ClinicalTrials.gov Identifier: NCT02426684) at Cedars-Sinai Medical Center with Professor Stanley Jordan as principal investigator. The study aimed at enrolling 10 to 20 patients. Patients had donor specific antibodies (DSAs) and a positive cross-match test prior to IdeS

    Increase of number of shares and votes in Hansa Medical AB (publ)

    As previously announced, the general meeting of Hansa Medical AB (publ) has, on December 22, 2017, resolved on a share issue of 2,752,526 ordinary shares. The company’s registered share capital and number of outstanding shares and votes have thus increased during December.As of December 29, 2017, the total number of registered and outstanding shares of Hansa Medical amounts to 38,208,386 of which 37,807,386 are ordinary shares and 401.000 are C shares. As of December 29, 2017, the number of votes in Hansa Medical amounts to 37,847,486 and the registered share capital amounts to SEK 38,208,

    Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)

    On 22 December, 2017, Hansa Medical AB (publ) held an extraordinary general meeting. The following resolutions, among others, were passed at the general meeting.Approval of the board of directors’ resolution to issue new ordinary shares The general meeting resolved to approve the board of directors’ resolution, resolved 29 November 2017, to carry out a directed issue of not more than 2,752,526 new ordinary shares, entailing an increase in the share capital of not more than SEK 2,752,526. The right to subscribe for the new ordinary shares in the directed issue shall, with deviation from

    Notice of Extraordinary General Meeting of Hansa Medical AB (publ)

    The shareholders of Hansa Medical AB (publ) are summoned to attend the Extraordinary General Meeting on 22 December 2017, at 14.00 CET at Hansa Medical’s offices on Scheelevägen 22, Lund, Sweden.  The shareholders of Hansa Medical AB (publ) are hereby summoned to attend the Extraordinary General Meeting (“EGM”) on 22 December 2017, at 14.00 CET at Hansa Medical’s offices on Scheelevägen 22, Lund, Sweden. Registration starts at 13.30 CET and will be possible until the meeting starts.  Right to participate Those who have been recorded as shareholders in the share register kept by

    Hansa Medical's Nomination Committee for the AGM 2018 appointed

    In accordance with the decision of the Annual General Meeting on May 23, 2017, a Nomination Committee for the Hansa Medical AGM 2018 has been formed. Based on the list of shareholders as of 31 August 2017, the three largest shareholders have been contacted and invited to each appoint a representative to the Nomination Committee. The Nomination Committee consists of Erika KjellbergEriksson representing Nexttobe AB, Max Mitteregger representing Gladiator and Sven Sandberg representing Thomas Olausson. The Nomination Committee also includes the chairman of the board, Birgit Stattin Norinder, as

    Hansa Medical Interim report July – September 2017

    July-September in brief ›› Combined data from three independent clinical Phase II studies with Hansa Medical’s lead candidate IdeS was published in The New England Journal of Medicine 2017;377:442-53, August 3, 2017 issue. Data from these studies show that IdeS effectively reduces HLA antibodies and enables patients with very poor prognosis, who are unlikely to find a kidney donor, to be transplanted. Importantly, patients were doing well with good kidney function at last follow up. ›› Patient enrollment on target to have all patients recruited and treated by the end of 2017 in two

    Hansa Medical to Host Conference Call to Provide Third Quarter 2017 Business Update

    On 14 November 2017, at 08:00AM CEST, Hansa Medical will publish its report for the third quarter of 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CEST. The event will be hosted by Hansa Medical’s CEO and President, Göran Arvidson, and the presentation will be held in English.Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will also be made available after the call. To participate in the telephone conference, please call: SE:

    Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies

    Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, today announced that on its Capital Markets Days in Stockholm (today, October 3) and London (October 4), the company will present an update on the number of patients included in the company’s clinical studies.The update will present the status of the ongoing clinical Phase II studies with the lead drug candidate IdeS in kidney transplantation, where the number of patients treated with IdeS prior to kidney transplantation now amounts to 42. The ongoing studies are expected to be

    Hansa Medical announces agenda for Capital Markets Days in Stockholm & London

    Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, announces the agenda for the Capital Markets Days for investors, analysts and media in Stockholm on Tuesday 3 October from 1:00 PM – 4:30 PM CEST and in London on Wednesday 4 October from 12:00 PM – 2:30 PM BST.The event in Stockholm will be held at Wallenbergsalen, IVA Konferenscentrum, Grev Turegatan 16, and the event in London will be held at the offices of FTI Consulting, 200 Aldersgate, EC1A 4HD. Both events will be webcast. The meeting will include data from studies

    SAVE THE DATE: Tuesday 3 & Wednesday 4 October 2017, Hansa Medical’s Capital Markets Days, Stockholm & London

    Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, will host Capital Markets Days for investors, analysts and media in Stockholm on Tuesday 3 October, 1:00 PM – 5:00 PM CET and in London on Wednesday 4 October at 12:00 PM BST (1:00 PM CET / 7:00 AM ET).The event in Stockholm will be held at Wallenbergsalen, IVA Konferenscentrum, Grev Turegatan 16, and the event in London will be held at the offices of FTI Consulting, 200 Aldersgate, EC1A 4HD. Both events will be webcast. Members of Hansa Medical’s management team will

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media